MiniMed
This article was originally published in The Gray Sheet
Executive Summary
Nets $141.2 mil. from a secondary offering of approximately 2.6 mil. shares of common stock at $68.375 each, including overallotment shares. The infusion system maker had planned an offering of 2.3 mil. shares, including 300,000 shares offered by a selling shareholder (1"The Gray Sheet" July 5, p. 26). Overallotment shares included 172,500 purchased from the company and 172,500 shares from a selling stockholder. The deal was underwritten by Warburg Dillon Read LLC. Co-managers of the offering included Hambrecht & Quist LLC, ING Baring Furman Selz LLC and Volpe Brown Whelan & Company
You may also be interested in...
MiniMed Glucose Monitor Approval Sweet As Stock Gains 30% In June
FDA approval of MiniMed's continuous glucose monitoring system (CGMS) June 16 helped sweeten the company's stock price during the month.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.